Lgt Group Foundation Gilead Sciences, Inc. Transaction History

Lgt Group Foundation

$6.53 Billion
Q2 2024

A detailed history of Lgt Group Foundation transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Lgt Group Foundation holds 25,694 shares of GILD stock, worth $2.15 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

25,694

Previous 27,404 6.24%

Holding current value

$2.15 Million

Previous $2.01 Million 12.21%

% of portfolio

0.03%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$63.15 - $72.88 $107,986 - $124,624	-1,710 Reduced 6.24%	25,694 $1.76 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $153,038 - $186,626	-2,138 Reduced 7.24%	27,404 $2.01 Million
Q4 2023 Feb 06, 2024	SELL	$73.27 - $83.09 $169,986 - $192,768	-2,320 Reduced 7.28%	29,542 $2.39 Million
Q3 2023 Nov 06, 2023	BUY	$73.94 - $80.67 $105,734 - $115,358	1,430 Added 4.7%	31,862 $2.39 Million
Q2 2023 Jul 27, 2023	SELL	$76.01 - $86.7 $290,586 - $331,454	-3,823 Reduced 11.16%	30,432 $2.35 Million
Q1 2023 Apr 20, 2023	SELL	$77.31 - $88.08 $3.69 Million - $4.2 Million	-47,668 Reduced 58.19%	34,255 $2.84 Million
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $2.02 Million - $2.9 Million	-32,412 Reduced 28.35%	81,923 $7.03 Million
Q3 2022 Oct 19, 2022	BUY	$59.54 - $68.01 $16,611 - $18,974	279 Added 0.24%	114,335 $7.05 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $379,162 - $427,050	6,569 Added 6.11%	114,056 $7.05 Million
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $2.25 Million - $2.82 Million	38,810 Added 56.51%	107,487 $6.41 Million
Q4 2021 May 03, 2022	BUY	$64.88 - $73.64 $4.46 Million - $5.06 Million	68,677 New	68,677 $4.99 Million

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lgt Group Foundation, based on Form 13F filings with the SEC.

News

Stay updated on Lgt Group Foundation with notifications on news.

Account

Lgt Group Foundation Gilead Sciences, Inc. Transaction History